This early-stage study tests a gene therapy called NG101 for wet age-related macular degeneration (wAMD), a leading cause of vision loss. About 20 adults aged 50-89 who need frequent eye injections will receive a one-time treatment under the retina. The goal is to see if it is sa…
Phase: PHASE1, PHASE2 • Sponsor: Elisigen, Inc. • Aim: Disease control
Last updated May 08, 2026 12:04 UTC